Teva Pharmaceutical Industries recently launched generic versions of Sanofi's enoxaparin sodium injection (Lovenox) and Pfizer's linezolid injection (Zyvox).
Teva Pharmaceutical Industries recently announced the US launch of its generic versions of Sanofi’s enoxaparin sodium injection (Lovenox) and Pfizer’s linezolid injection (Zyvox).
Enoxaparin sodium injection, which is available in 7 dosage strengths, is indicated for prophylaxis of deep vein thrombosis (DVT) in patients undergoing abdominal surgery or hip or knee replacement surgery, or those with severely restricted mobility during acute illness. The drug is also indicated for the treatment of acute DVT.
Linezolid injection is indicated for the treatment of the several infections caused by susceptible Gram-positive bacteria, including nosocomial pneumonia, community-acquired pneumonia, Vancomycin-resistant Enterococcus faecium infections, uncomplicated skin and skin structure infections, and complicated skin and skin structure infections without concomitant osteomyelitis, such as diabetic foot infections.
Earlier this month, Teva launched its injectable nafcillin and reintroduced its injectable leucovorin calcium 100 mg/vial, methylprednisolone acetate injectable suspension 40 mg/mL, and ondansetron injection 2 mg/mL.
“Teva is committed and focused on building a stronger generic injectable business globally,” said Teva Global Generic Medicines President and CEO Siggi Olafsson in a press release. “With the launch of enoxaparin sodium injection and linezolid injection, accompanied by the reintroduction of 3 generic injectable products, we are leveraging the strength of our internal and external resources to deliver the right portfolio as part of our growth strategy.”
According to IMS data, Lovenox and Zyvox has annual US sales of approximately $1.8 billion and $464 million, respectively.